NSE: LALPATHLAB · 4 November 2026
- Dr. Lal Path Labs Ltd. shares surged 5.39% on November 4, 2026, closing near the day's high at ₹2,029.40 compared to its previous close of ₹1,925.70. The stock traded within a daily range of ₹1,901.00 and ₹2,049.00, accompanied by heavy market participation.
- acquisition of 70% stake in SN Genelab Private Limited ( S N Gene ) from its existing Shareholders. Post acquisition, S N Gene shall become a Subsidiary of the Company.
- Trading volume was 3.19 times the 20-day average daily volume.
Why is Dr. Lal Path Labs share price rising on 4 November 2026?
Dr. Lal Path Labs Ltd. shares surged 5.39% on November 4, 2026, closing near the day's high at ₹2,029.40 compared to its previous close of ₹1,925.70. The stock traded within a daily range of ₹1,901.00 and ₹2,049.00, accompanied by heavy market participation.
The broader market and sector indices showed positive momentum, with the Nifty rising 0.63% and the Nifty Pharma sector benchmark gaining 0.42%. Dr. Lal Path Labs outperformed both the broader market and its industry peers, extending its recent positive trajectory with a 6.38% return over the past 5 trading days and a 4.11% gain over the past 20 trading days.
The upward price movement coincided with the release of the company's strong financial results for the quarter and half year ended September 30, 2026. Consolidated revenue grew 19.6% year-on-year to ₹874 crore in the second quarter of fiscal 2027, while profit after tax jumped 27.5% to ₹194 crore. Additionally, the board announced a second interim dividend of ₹5 per share, with November 11, 2026, set as the record date for payment.
7.35 lakh shares traded by 4 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.30 lakh shares (3.19 times). The five-day average daily volume was 2.00 lakh shares. Separately, the NSE report for 4 November 2026 showed 2.61 lakh shares delivered, representing 35.50% of that day’s traded volume. The same report recorded 84,562 trades.
The 5.39% rally in Dr. Lal Path Labs shares is strongly supported by the release of Q2 FY27 financial results showing a 19.6% increase in revenue and a 27.5% jump in profit after tax, alongside significantly heightened trading volumes.
Latest Company Developments
acquisition of 70% stake in SN Genelab Private Limited ( S N Gene ) from its existing Shareholders. Post acquisition, S N Gene shall become a Subsidiary of the Company.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 18.68% on 30 September 2026. This compares with 18.79% on 30 June 2026, a change of -0.11 percentage points.
The filing reported 36 MF/UTI holders.
What to Watch Next
- Execution of international expansion plans including further investments in LPL Dubai and Sunshine Healthcare Ghana
- Adoption and performance trends of SwasthFit preventive wellness packages
- Sustained delivery and cash volume participation above the 20-day average
- Progress on recent diagnostic network integrations and new lab additions
More Dr. Lal Path Labs news and dated analysis →
Frequently Asked Questions
What is the latest Dr. Lal Path Labs company news?
acquisition of 70% stake in SN Genelab Private Limited ( S N Gene ) from its existing Shareholders. Post acquisition, S N Gene shall become a Subsidiary of the Company.
How strong was Dr. Lal Path Labs’s trading volume?
7.35 lakh shares traded, 3.19 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.